If you’re researching medical weight loss, you’ve likely run into two names again and again: semaglutide and tirzepatide. Both are prescription medications used for weight management and metabolic health, and both have strong clinical evidence behind them — but they aren’t identical, and the right choice depends on your health history, goals, and how your body responds. This page walks through how each medication works, how they compare on results and side effects, and what a provider actually weighs when recommending one over the other. It’s meant to help you ask better questions at your consultation — not to replace one.
Semaglutide is a GLP-1 receptor agonist — it mimics a natural hormone (glucagon-like peptide-1) that your gut releases after eating. It slows stomach emptying, increases feelings of fullness, and helps regulate blood sugar. It’s the active ingredient behind the brand names Ozempic and Wegovy, and it’s been used clinically for weight management and type 2 diabetes for several years, giving it one of the longer real-world track records among GLP-1 medications.
Tirzepatide is a newer medication that acts on two hormone pathways instead of one: it’s a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. The added GIP activity is thought to be part of why tirzepatide has shown somewhat greater average weight loss in clinical trials compared to semaglutide. It’s the active ingredient behind Mounjaro and Zepbound.
Both medications reduce appetite and slow digestion, which is why both are effective for weight loss. The practical difference is that tirzepatide’s dual-hormone action tends to produce a stronger effect on appetite suppression and blood sugar control for many patients, while semaglutide has a longer history of use and a well-established safety profile.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Hormone pathways | GLP-1 only | GLP-1 and GIP (dual action) |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
| Typical dosing | Once-weekly injection | Once-weekly injection |
| Average weight loss in trials* | Roughly 15% of body weight over ~68 weeks (STEP trial data) | Roughly 20-21% of body weight over ~72 weeks (SURMOUNT trial data) |
| Track record | Longer-established, more real-world data | Newer, growing rapidly, strong trial data |
| Common side effects | Nausea, constipation, diarrhea, fatigue | Nausea, diarrhea, constipation, decreased appetite |
*Figures reflect published clinical trial averages and are not a guarantee of individual results. Weight loss varies significantly from person to person based on dose, adherence, starting weight, diet, and activity level.
The two medications share a very similar side effect profile, since both work through related mechanisms. Most side effects are gastrointestinal and tend to be strongest during the first few weeks or after a dose increase, often easing as your body adjusts.
Dose titration — starting low and increasing gradually — is one of the main tools a provider uses to reduce side effects with either medication. This is part of why medically supervised dosing matters more than simply obtaining a prescription.
Both medications are typically priced by dose and supply length, and insurance coverage varies widely depending on your plan and whether your use case qualifies as medically necessary. Compounded formulations (when appropriate and prescribed under proper medical oversight) can sometimes offer a different price point than brand-name product. Because pricing changes and depends on your specific dose and plan, your exact cost is confirmed during your consultation rather than quoted generically here.
There’s no universally “better” option — the right medication depends on your body, your health history, and your goals. Here’s how a provider generally thinks through it:
You might lean toward semaglutide if:
You might lean toward tirzepatide if:
Either way, your provider will also consider:
Yes, this is a common conversation in medical weight management, and switching is sometimes recommended if you’ve plateaued or experienced side effects. Any switch should be guided by your provider, since dosing isn’t a simple one-to-one conversion between the two medications.
Treatment length is individualized. Some patients use GLP-1 therapy for a defined period alongside lifestyle changes, while others continue longer-term to maintain metabolic health. This is a core part of what your provider will map out with you.
Both are FDA-approved and have substantial clinical trial data behind them. As with any prescription medication, they carry risks and aren’t appropriate for everyone — a thorough medical history and lab review is part of a responsible prescribing process.
Weight regain after stopping GLP-1 therapy is a well-documented consideration, which is part of why treatment plans are built around sustainable habits (nutrition, activity, muscle preservation) alongside the medication, not the medication alone.
The comparison above is a starting point — the actual decision depends on your labs, your health history, and how your body responds over time. At The Whole You Wellness Center, we build your plan around your specific case rather than defaulting to one medication for everyone.
Schedule a consultation at The Whole You Wellness Center in St. Peters, Missouri, and we’ll review your health history and goals together to determine whether semaglutide, tirzepatide, or another approach makes the most sense.
*This page is for general education and does not replace a personalized medical evaluation. Individual results and appropriate treatment vary by patient.*
Schedule a consultation at The Whole You Wellness Center in St. Peters, Missouri, and we’ll review your health history and goals together to determine whether semaglutide, tirzepatide, or another approach makes the most sense.
